美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) 15/01/2031

1.09

+0.09019.01%

盤後：1.090.00000.00%16:18 EDT

成交量：3.59萬

成交額：3.87萬

市值：- -

市盈率：- -

高：1.11

開：1.00

低：0.9950

收：0.9999

52周最高：1.40

52周最低：0.6100

股本：- -

流通股本：- -

量比：4.93

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Briacell啓動加拿大首個臨床站點——Sunnybrook，用於轉移性乳腺癌關鍵性III期試驗

Briacell與富士膠片生物技術加州公司就Bria-IMT達成生產協議

Briacell公司達成生產協議，為三期臨床及商業化量產鋪路

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BCTXL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCTXL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXL\",,,,,undefined,":{"symbol":"BCTXL","market":"US","secType":"STK","nameCN":"BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) 15/01/2031","latestPrice":1.09,"timestamp":1787342400000,"preClose":0.9999,"halted":0,"volume":35861,"hourTrading":{"tag":"盘后","latestPrice":1.09,"preClose":1.09,"latestTime":"16:18 EDT","volume":3,"amount":3.1365,"timestamp":1787343534656,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.09010901090109018,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0.0901,"latestTime":"08-21 16:00:00 EDT","open":1,"high":1.11,"low":0.995,"amount":38651,"amplitude":0.115012,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9999,"postHourTrading":{"tag":"盘后","latestPrice":1.09,"preClose":1.09,"latestTime":"16:18 EDT","volume":3,"amount":3.1365,"timestamp":1787343534656,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.926096830192339},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXL\",,,,,undefined,":{"symbol":"BCTXL","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.926096830192339,"shares":0,"dividePrice":0,"high":1.11,"amplitude":0.115012,"preClose":0.9999,"low":0.995,"week52Low":0.61,"pbRate":"--","week52High":1.4,"institutionHeld":0,"latestPrice":1.09,"eps":0,"divideRate":0,"volume":35861,"delay":0,"ttmEps":0,"open":1,"prevYearClose":0.65,"prevWeekClose":0.85,"prevMonthClose":0.92,"prevQuarterClose":0.89,"fiveDayClose":0.85,"twentyDayClose":0.95,"sixtyDayClose":0.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCTXL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCTXL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCTXL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCTXL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1197584324","title":"Briacell啓動加拿大首個臨床站點——Sunnybrook，用於轉移性乳腺癌關鍵性III期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1197584324","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197584324?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 19:37","pubTimestamp":1784201833,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp. 已正式启动其在加拿大的首个临床研究中心——位于多伦多的Sunnybrook健康科学中心，以推进其针对转移性乳腺癌的关键性III期临床试验。这一进展标志着该公司核心候选疗法Bria-IMT™联合检查点抑制剂的研究进入了一个重要阶段，旨在评估其在难治性转移性乳腺癌患者中的安全性与有效性。Sunnybrook作为加拿大顶尖的癌症研究与治疗机构之一，其参与有望加速患者招募并增强试验数据的权威性。此次III期试验的成功与否，对Briacell的未来商业化前景及股价走势可能产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116025944","title":"Briacell與富士膠片生物技術加州公司就Bria-IMT達成生產協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1116025944","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116025944?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 19:34","pubTimestamp":1784115281,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp宣布，已与富士胶片生物技术加州公司就其实验性癌症免疫疗法Bria-IMT达成了生产安排。该协议旨在为Bria-IMT的临床开发和未来潜在的商业化提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107769441","title":"Briacell公司達成生產協議，為三期臨床及商業化量產鋪路","url":"https://stock-news.laohu8.com/highlight/detail?id=1107769441","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107769441?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 19:33","pubTimestamp":1784115213,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp宣布达成一项关键的生产安排。此举旨在确保其候选疗法在关键三期临床研究阶段拥有充足的生产能力，并为未来潜在的大规模商业化生产奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXL","BCTXZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BCTXL\",params:#limit:6,delay:false,,,undefined,":[]}}